RGBP (Regen BioPharma) Ending Cash Position: $0.00 Mil (As of Mar. 2026)


What is Regen BioPharma Ending Cash Position?

Regen BioPharma RGBP +7.14% Ending Cash Position is $0.00 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

Regen BioPharma's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.00 Mil.

Regen BioPharma's quarterly Ending Cash Position declined from Sep. 2025 ($0.07 Mil) to Dec. 2025 ($0.01 Mil) and declined from Dec. 2025 ($0.01 Mil) to Mar. 2026 ($0.00 Mil).

Regen BioPharma's annual Ending Cash Position declined from Sep. 2023 ($0.12 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Sep. 2025 ($0.07 Mil).

Regen BioPharma Ending Cash Position Related Terms

Regen BioPharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Ending Cash Position Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.05 0.12 0.00 0.07

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.07 0.01 0.00

Regen BioPharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Regen BioPharma's Ending Cash Position for the fiscal year that ended in Sep. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.002+0.068
=0.07

Regen BioPharma's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.004+-0.004
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.00 Mil mean?
Regen BioPharma (RGBP) has a Ending Cash Position of $0.00 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Regen BioPharma and its competitors.
Is Regen BioPharma's Ending Cash Position too high?
Regen BioPharma's current Ending Cash Position is $0.00 Mil.
How does Regen BioPharma's Ending Cash Position compare to SIGY and ENDV?
Regen BioPharma's Ending Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current Ending Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.3% below its estimated fair value. The current Ending Cash Position is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Ending Cash Position is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.